Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

FDA-defined valvulopathy in patients treated with lorcaserin and in

the control group did not meet predetermined stopping criteria. The

review also confirmed that the rate of FDA-defined valvulopathy in the

placebo group is consistent with Arena's statistical powering

assumptions used in the design of the pivotal trial program to monitor

patients for any increased risk of developing valvulopathy.

-- Completed the sale to an affiliate of BioMed Realty Trust, Inc., or

BioMed, of three properties owned and occupied by Arena and the

assignment to BioMed of an option to purchase a fourth property

currently leased and primarily occupied by Arena. Arena received net

proceeds of $48.5 million for the properties and the purchase option.

Concurrently with the closing of the transaction, Arena leased back

the three properties sold to BioMed under leases with 20-year terms

and two consecutive options to extend such terms for five years each.

As part of the transaction, Arena also retained the option to purchase

from BioMed all the properties included in the transaction on the

10th, 15th or 20th anniversary of the execution date of the leases.

-- Completed patient enrollment in the BLOOM trial, a double-blind,

randomized and placebo-controlled trial that enrolled over

3,100 patients at approximately 100 sites in the United States.

Arena's 2008 Highlights to Date

-- Announced the initiation of a Phase 1 clinical trial of a second

generation oral niacin receptor agonist intended for the treatment of

atherosclerosis under Arena's partnership with Merck.

-- Entered into strategic cooperation agreements with Siegfried Ltd that

are primarily related to the manufacturing of lorcaserin, which is

expected to be necessary for Arena'
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Dallas, Texas (PRWEB) November 26, 2014 ... Bifluoride Industry” is a professional and in-depth research ... Ammonium Bifluoride information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
(Date:11/26/2014)... and PHILADELPHIA , Nov. 26, ... demanding and unforgiving environments. Human exploration of space requires ... to ensure mission safety and success, and prevent potential ... for mission success, little is known about how cognition ... cognition are primarily affected. Now, Penn Medicine ...
(Date:11/26/2014)... 2014 PMG Research, Inc. announced ... is a network of sites that provide clinical research services ... million patient lives through its partnerships with large physician practices ... hub site locations in the Southeastern United States and spans ... the board will be held by: Dr. Robert ...
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, the ... Awards for outstanding creative achievement by its marketing and ... the organization’s top honor, in the Branding category for ... April of this year. The event showcased top speakers ... was awarded a Gold MarCom Award in the Special ...
Breaking Biology Technology:Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2
... Ltd., a,privately-held drug development company with its headquarters ... new Phase IIa clinical testing of,ProtoCure(TM) emulsion cream, ... vehicle-controlled study is designed to,evaluate the tolerability, pharmacokinetics, ... of 18 subjects with mild to moderate plaque ...
... through non core divestitures - , - Caliper signs ... , - Non-cash restructuring and goodwill impairment charge ... Caliper Life Sciences, Inc. (Nasdaq: CALP ), today ... 2008. Fourth quarter revenues were $36.7 million, a decline ...
... Simcere Pharmaceutical Group,("Simcere" or the "Company,) (NYSE: ... pharmaceuticals and manufacturer of the patented,anti-cancer biotech product Endu ... and fiscal year ended December 31, 2008. , , ... revenue increased to RMB 466.9 million (US$68.4 million) for ...
Cached Biology Technology:BioCis Pharma Starts Phase IIa Trial in Psoriasis 2Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 2Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 3Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 4Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 5Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 6Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 7Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 8Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 9Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 10Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 11Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 12Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 13Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 14Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 2Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 3Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 4Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 5Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 6Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 7Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 8Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 9Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 10Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 11Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 12Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 13
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... - The meters-long, carnivorous "shrimp" from hell that once ruled the ... a real softy, it turns out. A new 3-D modeling of ... parts were not hard like teeth, but flexible, shows that the ... of trilobites and other such creatures of the early seas. ...
... Environmental Pollution " details successful experiments at the ... the abiotic (non-biological) transformation and absorption of four ... these estrogen hormones by more than 80 percent ... since it could point to inexpensive treatment technologies ...
... courses of antibiotics can leave normal gut bacteria harbouring ... treatment, say scientists writing in the latest issue of ... researchers believe that this reservoir increases the chances of ... survival and suggesting that the long-term effects of antibiotic ...
Cached Biology News:Earth's first great predator wasn't 2UC research: Rabbit's food brings luck in decreasing estrogen levels in wastewater 2UC research: Rabbit's food brings luck in decreasing estrogen levels in wastewater 3Antibiotics have long-term impacts on gut flora 2
... innovation from Magnetofection technology, SilenceMag is ... available. Simple, rapid and easy to ... non toxic. Specifically designed for siRNA ... at very low doses of siRNA.,SilenceMag ...
... C 4 H 10 O 2 ... PRODUCT SPECIFICATIONS Form: White crystalline powder ... 97% Identity: By IR Melting Point: ... Oxidized DTT: less than or equal ...
... Feature Extraction Software reads ... files to prepare microarray data ... , * one 2-year ... for NFP/Academic accounts , * ...
... for data analysis , Automatic grid, subgrid and ... template assignment , ... Extensive background and signal options to optimize, ... results , ...
Biology Products: